Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 1.00 |
| ▸ | CCR3 | P51677 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetoacetic Acid SCHEMBL28783696 | 0.91 | GAA (0.82) | GAACCR3MEN1KMT2AALDH1A1 | |
| SCHEMBL6153469 | 0.89 | GAA (0.80) | GAACCR3MEN1KMT2AALDH1A1 | |
| SCHEMBL27758186 | 0.86 | GAA (0.76) | GAACCR3MEN1KMT2AALDH1A1 | |
| SCHEMBL2004615 | 0.84 | CCR3 (1.00) | GAACCR3MEN1KMT2AALDH1A1 | |
| SCHEMBL4274161 | 0.83 | GAA (0.71) | GAAMEN1KMT2A | |
| SCHEMBL7404217 | 0.83 | GAA (0.70) | GAAMEN1KMT2ALMNAHTT | |
| SCHEMBL8191786 | 0.82 | CCR3 (0.96) | GAACCR3MEN1KMT2AALDH1A1 | |
| SCHEMBL7977320 | 0.82 | CCR3 (0.96) | GAACCR3MEN1KMT2AALDH1A1 | |
| SCHEMBL6154064 | 0.82 | GAA (0.70) | GAAMEN1KMT2A | |
| SCHEMBL6070072 | 0.82 | GAA (0.70) | GAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101341125-B | New phenanthridine derivatives as bradykinin antagonists | RICHTER GEDEON NYRT | 2012-10-10 | — | — | CN | disclosed |
| CN-101341125-A | New phenanthridine derivatives as bradykinin antagonists | RICHTER GEDEON NYRT (HU) | 2009-01-07 | — | — | CN | disclosed |
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | GAA 2875/4885CCR3 2563/4885MEN1 1993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.